France· FR:69972332
EMGALITY 120 mg, solution injectable en stylo pré-rempli
A medicinal product containing galcanézumab, registered in France by ELI LILLY NEDERLAND BV (PAY-BAS).
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- GALCANÉZUMAB
- Manufacturer
- ELI LILLY NEDERLAND BV (PAY-BAS)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
- cip1334009301704581 seringue préremplie en verre de 1 mL en stylo prérempli
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Galcanézumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaEMGALITYEli Lilly Nederland B.V., Utrecht
- United StatesEMGALITYEli Lilly and Company
- CanadaEMGALITYELI LILLY CANADA INC
- FinlandEmgalityEli Lilly Nederland B.V.
- IcelandEmgalityEli Lilly Nederland B.V.*
- SwitzerlandEmgality
- SpainEMGALITY 120 MG SOLUCION INYECTABLE EN JERINGA PRECARGADAEli Lilly Nederland B.V.
- BelgiumEmgality 120 mgEli Lilly Nederland
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Emgality
- Liechtenstein · Emgality
- Norway · Emgality
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/df500730-b6eb-4336-94e8-35c9381bf5bf GET /v1/drugs/df500730-b6eb-4336-94e8-35c9381bf5bf?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "69972332",
"date_amm": "2018-11-14",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/18/1330",
"substance": "GALCANÉZUMAB",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution injectable",
"voies_administration": "sous-cutanée",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about galcanézumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.